Document Detail

Development of a hepatitis C virus vaccine.
MedLine Citation:
PMID:  12691469     Owner:  NLM     Status:  MEDLINE    
Any program aimed at the development of a vaccine should consider several important issues because they may greatly influence the choice of immunogen used in the vaccine, the delivery system selected for its application, the population to be vaccinated, and the type of vaccine to be developed (ie, preventive or therapeutic). These issues concern the epidemiology of the infectious disease targeted, the actual routes of transmission, the antigenic diversity of the infectious agent, the existing therapies, and their rate of success. In the case of hepatitis C virus, a viral agent whose clinical existence was recognized in the 1970s but which was only identified by the use of molecular cloning technology in the late 1980s, some of these issues are particularly relevant.
Genevieve Inchauspé; Stephen Feinstone
Related Documents :
16290279 - Risks and benefits of immunizing pregnant women: the risk of doing nothing.
8108849 - Diarrhoeal disease: current concepts and future challenges. diarrhoeal disease and vacc...
17023919 - Intestinal parasitic infections.
16451109 - Progress towards an effective syphilis vaccine: the past, present and future.
1765109 - The epidemiology and prevention of disease caused by haemophilus influenzae type b.
20854759 - Vaccines: specific features, simulation of impact and medico-economic modelling.
15802609 - Vaccines against bacterial meningitis.
8041879 - An end to manicheism.
12702129 - Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsule...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinics in liver disease     Volume:  7     ISSN:  1089-3261     ISO Abbreviation:  Clin Liver Dis     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-04-14     Completed Date:  2003-05-15     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9710002     Medline TA:  Clin Liver Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  243-59, xi     Citation Subset:  IM    
Unité Mixte CNRS-BioMérieux, UMR 2142, Ecole Normale Supérieure, 46 Allée d' Italie, Lyon 17-6934, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hepacivirus / immunology*
Hepatitis C / immunology*,  prevention & control,  virology
Pan troglodytes
Vaccination / methods
Vaccines, Attenuated / immunology,  standards
Vaccines, Combined / immunology,  standards
Vaccines, DNA / immunology,  standards
Vaccines, Subunit / immunology,  standards
Viral Hepatitis Vaccines / immunology*
Reg. No./Substance:
0/Vaccines, Attenuated; 0/Vaccines, Combined; 0/Vaccines, DNA; 0/Vaccines, Subunit; 0/Viral Hepatitis Vaccines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New therapies on the horizon for hepatitis C: are we close?
Next Document:  Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis...